

Characteristics and Determinants of Adiposity in Pediatric Cancer Survivors

Tracie L. Miller¹, Stuart R. Lipsitz², Gabriela Lopez-Mitnik¹, Andrea S. Hinkle³, Louis S. Constine⁴, M. Jacob Adams⁵, Carol French⁶, Cynthia Proukou³, Amy Rovitelli⁶, and Steven E. Lipshultz¹

Abstract

Background: Adiposity and the diseases associated with it, including cardiovascular disease, are emerging long-term complications of pediatric cancer survivors. Direct evaluations of adiposity and comparisons to contemporary controls that can differentiate recent trends in obesity from cancer-related treatments and sequelae are limited.

Methods: We evaluated demographic, treatment, lifestyle, and endocrine factors at the time of dual-energy X-ray absorptiometry testing in 170 non-Hispanic white survivors and 71 sibling controls, and compared three measures of adiposity [body mass index (BMI), total body fat, and trunk fat]. For the survivors alone, we determined factors independently associated with BMI and body fat.

Results: Survivors were at 12 years since diagnosis; 58% had leukemia or lymphoma. BMI did not differ between groups. Among males, body fat was greater in survivors than in controls (25.8% versus 20.7%; $P = 0.007$), as was trunk fat (26.7% versus 21.3%; $P = 0.008$). Total or trunk fat did not differ among females. Cholesterol, triglycerides, low-density lipoprotein cholesterol, and television viewing hours were higher among male survivors than in controls. Independent factors associated with higher BMI and total and trunk fat included any cranial radiation and television viewing hours, whereas prior treatment with cyclophosphamide was associated with lower BMI and body fat measures.

Conclusions: Compared with siblings, male survivors have greater body fat and metabolic risks. Cranial irradiation and television hours are important risk factors for adiposity in pediatric cancer survivors.

Impact: Pediatric cancer survivors should be carefully monitored for cardiovascular risk factors and sedentary lifestyles. *Cancer Epidemiol Biomarkers Prev*; 19(8); 2013–22. ©2010 AACR.

Introduction

Treatments for pediatric cancer have advanced substantially in recent years. With more than 75% of childhood cancer survivors cured of their original disease, there are now >325,000 survivors of childhood cancer in the United States as of January 1, 2005 (1). With increased survival, attention has turned to improving the long-term quality of life that can be adversely affected by the late effects of cancer therapy. Common late effects of pediatric cancer therapies include secondary malignancy, cardiotoxicity, reduced pulmonary function, and

disturbed growth and pubertal development (2, 3).

Obesity and the diseases associated with it, including cardiovascular disease, are also emerging long-term complications found in pediatric cancer survivors. Problems with overweight can begin at diagnosis (4), during treatment (5), and can continue after therapy (6). The causes of adiposity in cancer survivors are not entirely understood; however, a number of contributors have been identified, including reduced physical activity (7), cranial irradiation with identified or presumed hormonal dysregulation (8, 9), family risk factors (10), and early adiposity rebound (11).

Despite the many theories about the mechanism of adiposity and altered metabolism in long-term survivors of childhood cancer, disease- and treatment-related determinants are not often isolated from lifestyle and genetic factors. With the increasing rates of obesity in children in the United States (12, 13) and its emerging importance on cardiovascular health (14), attributing adiposity to cancer-specific factors without comparison to children with comparable genetic and environmental conditions may produce misleading results. Because treatment recommendations for each cancer diagnosis can change over time, we believe that understanding general treatment

Authors' Affiliations: ¹Division of Pediatric Clinical Research, Department of Pediatrics, Miller School of Medicine, University of Miami, Miami, Florida; ²Division of General Medicine, Brigham and Women's Hospital, Boston, Massachusetts; Departments of ³Pediatrics, Hematology/Oncology; ⁴Radiation Oncology; ⁵Community and Preventive Medicine; and ⁶Pediatrics, Pediatric Cardiology, University of Rochester School of Medicine and Dentistry, Rochester, New York

Corresponding Author: Tracie L. Miller, Batchelor Children's Research Institute, Division of Pediatric Clinical Research, Department of Pediatrics (D820), Miller School of Medicine, University of Miami, P.O. Box 016820, Miami, FL 33101. Phone: 305-243-1423; Fax: 305-243-8475. E-mail: tracie.miller@miami.edu

doi: 10.1158/1055-9965.EPI-10-0163

©2010 American Association for Cancer Research.

and lifestyle factors associated with adiposity, regardless of initial cancer diagnosis, will be more generalizable to pediatric cancer survivors as they age decades later. Knowledge about risk factors for adiposity in cancer survivors may lead to new understandings about its causes and prevention.

The objectives of this study were to (a) compare measures of body fat and metabolic factors associated with body fat between a general cohort of pediatric cancer survivors and their siblings, and (b) determine adiposity risks in survivors of childhood cancer receiving a diverse array of treatments. This study builds on previous self-reported outcome-based studies (8, 9) by performing direct evaluations on the survivors and their siblings. We hypothesized, compared to a control group with similar genetic and environmental conditions, that pediatric cancer survivors would show higher levels of adiposity and that lifestyle- and cancer-specific treatments or sequelae would contribute to greater levels of adiposity.

Subjects and Methods

Subjects

Subjects were recruited from the Pediatric Oncology Long-term Survivor Clinic at the University of Rochester, Rochester, NY, between 1998 and 2003 as part of enrollment in a prospective, longitudinal study on cardiac risk factors (15). Patients were eligible for this study if they had been followed in this program for at least 3 years since their diagnosis. Amputees were excluded because of the potential for unreliable body composition studies. Subjects were no longer receiving chemotherapy or radiation and were cancer-free at the time of the current study.

Sibling controls were invited to participate at the time of enrollment for each patient. Ninety-four siblings were invited to participate, and 76 siblings enrolled in the study. If there was more than one sibling, the one closest in age was preferred, although not required. Sibling controls could not have a diagnosis or history of cancer and have other medical comorbidities. All sibling controls that participated in the study were included in the analyses.

The institutional review board at the University of Rochester approved the research protocol, and informed consent from the patient or parent/guardian and assent from the child (when appropriate) were obtained.

Main outcome variables

Body mass index. Body mass index (BMI), one of our primary outcome variables, is defined as weight/height² (kg/m²). BMI is a commonly used and validated measure of body fatness among children and adults (16). Weight and standing height were measured by the recommended techniques (17) at the study visit. BMI was classified as underweight, healthy weight, overweight, and obese, with the definitions applied that were appropriate for age and sex (18).

Total body fat and total trunk fat. Percent total body and trunk fat were determined by dual-energy X-ray absorptiometry (GE Lunar Prodigy DF 10370; Madison, WI) as previously described (19). A relatively noninvasive method that quantifies whole-body composition into fat-free and fat masses, dual-energy X-ray absorptiometry also assesses the regional distribution of body fat. Lunar software (version 6.10) was used to calculate body composition.

Data collection and covariates

Current clinical and laboratory data were collected during the same visit. Additional information (chemotherapy, radiation) was abstracted retrospectively from medical records. Baseline information was collected on age, sex, race, type of cancer, age at diagnosis, duration of treatment, time since completion of therapy, type of chemotherapy, and type and amount of radiation therapy. Cancer diagnosis was categorized as brain, embryonal, germ, leukemia, lymphoma, sarcoma, or other. All radiation that included the cranium was recorded. Chemotherapeutic categories included anthracyclines, prednisone, methotrexate, cyclophosphamide, and cisplatin and were not mutually exclusive. The number of hours per day spent watching television, as a surrogate marker for activity level, was recorded through a study questionnaire (20).

Laboratory serum biomarkers included markers of endocrine function [fasting insulin, estrogen, follicle-stimulating hormone, luteinizing hormone, insulin-like growth factor-1 (IGF-I), testosterone (males only), thyroid-stimulating hormone, free thyroxine] and a lipid fasting profile (total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and triglycerides). Values for these biomarkers were determined in a Clinical Laboratory Improvement Amendments–approved laboratory (Strong Memorial Hospital Clinical Laboratory, Rochester, NY). High-sensitivity C-reactive protein (CRP) was assayed by the N High Sensitivity CRP assay (Dade Behring).

Statistical methods

The first protocol visit for each participant was used for all statistical analyses. All analyses were done separately for males and females. First, cancer survivors were compared with controls on anthropometric and metabolic factors. Because anthropometric (such as weight) and metabolic (such as cholesterol) outcome variables change with age, all comparisons of these outcomes were age adjusted. In these bivariate analyses, the age-adjusted means were calculated from separate linear regression models for cancer survivors and controls, with age as a covariate in each model. When calculating *P* values for comparisons of age-adjusted means from cancer survivors and controls, general linear mixed models (21) were used to adjust the *P* value for a possible family effect from a sibling control and cancer survivors who are from the same family. In particular, to calculate

these *P* values, a mixed model was fit with a random sibling effect and covariates: age, cancer/control status, sex, and all possible interactions between sex and age and sex and cancer/control status. Fifty percent of cancer survivors did not have a matched control. However, analyses showed no systematic difference between groups. Thus, all survivors were used in the analyses to increase power.

Second, multivariate analyses were done in survivors, alone; on the outcomes BMI, percent body fat, and percent trunk fat; and with the covariates of type of cancer, type of chemotherapy, radiation, duration of treatment, time since completion of therapy, and hormonal factors [luteinizing hormone, follicular-stimulating hormone, testosterone (males only), IGF-I, free thyroxine]. All regression models were age adjusted. Our a priori hypotheses included analyses of our stated outcomes and predictors. Covariates were kept in a regression model for known biological effects (such as age) and were considered significant if the *P* value is <0.05.

We performed analyses on these restricted sets of variables. Because this analysis was exploratory, we did not adjust the type 1 error rate to account for multiple comparisons; thus, *P* values should be interpreted cautiously. The number of significant associations (*P* < 0.05) in these analyses is much greater than expected by chance if there were no associations in the data. All tests were two-tailed. The SAS statistical software package (SAS Institute) was used in the analyses.

Results

Patient characteristics

A total of 201 pediatric cancer survivors and 76 siblings were enrolled in the study; however, because the majority (90%) of the cohort was non-Hispanic white, we excluded 26 survivors and siblings of other ethnicities from data analyses. The remaining survivors were excluded because of previously defined exclusions (amputee). Thus, 170 pediatric cancer survivors and 71 siblings (controls) were included in this analysis.

Enrollment demographic and clinical characteristics of the study participants are shown in Table 1, and the profile of the long-term survivor population in the general clinic that has previously been reported was approximated (15).

Anthropometric characteristics

Among females, survivors were older than their siblings (20.3 versus 15.5 years; *P* = 0.004; Table 2). The survivors, after adjusting for age and sibling pair, were shorter and weighed less, although the BMIs were similar (24.3 kg/m² for siblings versus 23.6 kg/m² for survivors). Other body composition measures did not differ markedly between survivors and siblings. Thirty-six percent of female cancer survivors (*n* = 30) were classified as overweight or obese, compared with 48% of control females (*P* = 0.22).

Among males, survivors were older than their siblings (18.5 versus 16.6 years; *P* = 0.13; Table 2), although this did not reach statistical significance. Heights, weights, and BMIs, after adjusting for age and sibling pair, were similar between survivors and siblings. However, percent body fat (25.8% versus 20.7%; *P* = 0.007) and percent trunk fat (26.7% versus 21.3%; *P* = 0.008) were greater in survivors than in siblings. Thirty-seven percent of male cancer survivors (*n* = 32) were classified as overweight or obese, compared with 29% of control males (*P* = 0.40).

Metabolic factors and television viewing

For females, the age-adjusted IGF-I levels of survivors were significantly lower than controls (213.2 versus 283.8 ng/mL; *P* = 0.004). All other factors were similar in both groups (Table 3). For males, after adjusting for age and sibling pair, survivors had significantly lower free thyroxine (1.06 versus 1.32 ng/dL; *P* < 0.001), higher follicular-stimulating hormone (7.28 versus 4.92 μU/mL; *P* = 0.01), and lower IGF-I (197.9 versus 258.2 ng/mL; *P* = 0.04) values. Male survivors watched a greater number of hours of television than their siblings (2.3 versus 1.8 hours per day; *P* = 0.04).

Serum lipid levels that may be associated with, yet not causal for, higher BMI and body fat are compared in Fig. 1. For males, total cholesterol, low-density lipoprotein cholesterol, and triglycerides were significantly higher in survivors. No differences were found for females. High-sensitivity CRP was significantly higher in female survivors compared with siblings (0.35 versus 0.07 mg/dL; *P* = 0.02), but there were no differences among males (0.18 versus 0.09 mg/dL; *P* = 0.38). No differences were found in fasting insulin levels for either sex.

Predictors of adiposity in survivors

We performed bivariate (adjusting for age in all analyses) and multivariate analyses to identify specific factors associated with BMI and percent body and trunk fat in survivors. We analyzed data for males and females separately (Tables 4A–C).

For BMI in females, cranial irradiation and more television viewing hours were associated with greater BMI (*P* = 0.01 and 0.03, respectively), whereas exposure to cyclophosphamide and cisplatin were associated with a lower BMI (*P* = 0.01 and 0.04, respectively) in the bivariate analysis. In similar bivariate analyses for percent body fat and percent trunk fat in females, methotrexate, cranial irradiation, and more television hours had increased these outcomes, whereas past exposure to cyclophosphamide decreased them. For males, higher BMI was positively associated with IGF-I (*P* = 0.04) and lower BMI was associated with cyclophosphamide exposure (*P* = 0.008). Furthermore, bivariate results in a similar model for males showed cranial irradiation and more television viewing hours were associated with higher percent body fat and higher percent trunk fat.

Although not considered in the multivariate model, the diagnosis of leukemia, after adjusting for age and sex,

Table 1. Diagnosis and treatment history of 170 long-term survivors of pediatric cancer and 71 cancer-free siblings

Cancer survivors	All (170)	Females (83)	Males (87)
Mean age at study, y	19.38	20.34	18.48
Range, y	(5.9–39.7)	(5.9–39)	(6–39.7)
Mean age at diagnosis, y	7.5	8.44	6.51
Range, y	(0–24.1)	(0.42–17.7)	(0–24)
Females, <i>n</i> (%)	83 (49)		
Mean years since diagnosis	11.9	11.90	11.96
Range, y	(4.3–31.6)	(4.5–29.9)	(4.3–31.6)
Cancer diagnosis, <i>n</i> (%)			
Leukemia	63 (37)	32 (39)	31 (36)
Lymphoma	35 (21)	18 (22)	17 (20)
Embryonal	33 (20)	16 (19)	17 (20)
Brain	16 (9)	6 (7)	10 (11)
Sarcoma	16 (9)	9 (11)	7 (8)
Germ cell	4 (2)	2 (2)	2 (2)
Other	3 (2)		3 (3)
Chemotherapy, <i>n</i> (%) [*]			
Anthracycline	112 (66)	58 (70)	54 (62)
Prednisone	88 (52)	44 (53)	44 (50)
Methotrexate	80 (47)	39 (47)	41 (47)
Cyclophosphamide	72 (42)	36 (43)	36 (41)
Cisplatin	32 (19)	16 (19)	16 (18)
Any cranial radiation, <i>n</i> (%)	81 (48)	34 (41)	47 (54)
Sibling controls	All (71)	Female (33)	Male (38)
Mean age at study, y	16	15.53	16.58
Range, y	(5.3–45.9)	(5.9–31.3)	(5.3–45.9)

*Not mutually exclusive.

was associated with increased BMI (estimate 1.93; $P = 0.03$), body fat (estimate 4.36; $P = 0.005$), and trunk fat (estimate 0.02; $P = 0.04$). Furthermore, a history of brain tumor, after adjusting for age and sex, was also associated with increased BMI (estimate 3.54; $P = 0.02$) and total body fat (estimate 9.17; $P < 0.001$).

Multivariate models for females and males were then developed (Table 4A–C). For females, BMI was positively associated with age and negatively associated with cyclophosphamide exposure. Percent body and trunk fat were positively associated with age, cranial irradiation, television viewing hours, and negatively associated with cyclophosphamide use.

For males, BMI was independently and positively associated with age and IGF-I levels and negatively associated with cyclophosphamide use. Percent body and trunk fat in males were independently and positively associated with age, cranial irradiation, and television viewing hours. As an example, the male model in Table 4B shows that an average male cancer survivor who received cranial irradiation had 5.82% more body fat than an average male cancer survivor who did not receive cranial irradiation, after controlling for other characteristics.

Dose effect of cranial radiation on adiposity

We were especially interested in the effect of cranial radiation on adiposity because of the known effects of cranial irradiation on the hypothalamic/pituitary axes (22). Cranial radiation, as a categorical variable, and television viewing hours were the most consistent predictors of our outcomes in the multivariate analyses. We explored the effect of cranial radiation according to increasing dose (none, 0–20 Gy, and >20 Gy; Fig. 2) and after adjustment for age on our outcomes. Females who received any cranial radiation (compared with those who received none) had significantly higher percent body and trunk fat. There were no significant differences in body composition measures between those children who received 0 to 20 Gy and those who received >20 Gy of cranial irradiation. Although there were no statistically significant differences in BMI between these three radiation dose categories, BMI increased from 22.2 kg/m² (with no cranial irradiation) to 26.1 kg/m² when >20 Gy was administered.

The results were similar for males, with no significant differences in BMI by cranial irradiation dose. However, percent body and trunk fat both increased with any

Table 2. Adiposity characteristics of 170 pediatric cancer survivors and 71 sibling controls

Variable (mean, IQR)	Females			Males		
	Survivors (n = 83)	Controls (n = 33)	P	Survivors (n = 87)	Controls (n = 38)	P
Age, y	20.3 (14.2–26.2)	15.5 (12.2–17.9)	0.004	18.5 (12.4–23.4)	16.6 (10.8–19.9)	0.13
Height, cm	155.0 (147.7–163.1)	161.3 (158.1–169.3)	0.03	163.2 (152.7–173.9)	167.0 (160.5–178.2)	0.11
Weight, kg	57.9 (44.8–67.6)	63.4 (53.0–73.4)	0.14	64.9 (51.1–76.3)	66.2 (60.1–80.1)	0.68
BMI, kg/m ²	23.6 (19.0–26.4)	24.3 (22.0–27.6)	0.49	23.5 (20.6–24.9)	22.6 (19.9–26.3)	0.38
Body fat, %	36.3 (28.3–43.0)	34.5 (28.8–41.7)	0.43	25.8 (17.9–33.2)	20.7 (13.8–28.2)	0.007
Trunk fat, %	35.0 (25.9–43.4)	33.5 (26.9–41.6)	0.55	26.7 (19.3–34.8)	21.3 (13.3–29.2)	0.008

NOTE: Mixed models (SAS Proc Mixed) were used to estimate means by sex while adjusting for age and sibling pairs. Abbreviation: IQR, interquartile range.

cranial irradiation. Percent body and trunk fat did not differ between the radiation dose groups.

Discussion

In this study, we evaluated BMI, total body fat, and trunk fat in a convenience sample of pediatric cancer survivors with several tumor types from one geographic region of the United States. As opposed to focusing on original diagnoses, our analyses identified demographic, lifestyle (television viewing), and treatment-related factors associated with adiposity that can be applied to non-Hispanic white pediatric cancer survivors as a general group.

We compared anthropometric and metabolic indices associated with body fat between pediatric cancer survivors and their siblings. With ballooning rates of childhood obesity and its sequelae (12, 13), a comparison group is necessary to discriminate late cancer effects from contemporary trends. BMI was similar among male and female survivors, each compared with their siblings. More than one third of the cancer survivors met the

criteria for overweight or obese, yet these percentiles were not statistically different than the controls. However, male survivors had more trunk and total body fat than their siblings. Lipid profiles and television viewing were also different in male survivors. Cranial irradiation and television viewing were associated with higher total fat and trunk fat (not BMI) for both males and females.

Although not considered in the final model because of our objectives to study the effects of past treatment regimens, we found leukemia survivors and those with brain tumors to have higher estimates of body fat than those with other diagnoses. The associations between these diagnoses and body fat are likely confounded by these patients' past receipt of cranial irradiation. Because the location of the brain tumor may have produced specific abnormalities that would affect body fat, we considered this tumor type in the final model; however, this variable was not retained (data not shown).

Adiposity in survivors of childhood leukemia (8, 9, 23–27) and brain tumors (28, 29) has been studied. The prevalence of overweight and obesity, as measured by BMI, in childhood acute lymphoblastic leukemia

Table 3. Nononcologic predictors of obesity in 170 cancer survivors and 71 sibling controls

Variable (mean, IQR)	Females			Males		
	Survivors (n = 83)	Controls (n = 33)	P	Survivors (n = 87)	Controls (n = 38)	P
TSH, μ U/mL	2.27 (1.28–2.55)	2.04 (1.17–2.68)	0.52	2.19 (1.23–2.52)	1.96 (1.16–2.27)	0.43
T4, ng/dL	1.09 (1.00–1.24)	1.05 (1.00–1.10)	0.64	1.06 (1.00–1.10)	1.32 (1.00–1.30)	<0.001
FSH, μ U/mL	4.89 (1.74–6.52)	4.42 (2.77–5.93)	0.68	7.28 (3.00–9.30)	4.92 (1.84–5.00)	0.01
LH, μ U/mL	6.57 (0.95–6.12)	6.47 (1.57–8.37)	0.94	3.80 (1.84–5.14)	5.55 (1.58–3.97)	0.13
Estrogen, pg/mL	58.4 (20.00–70.23)	53.2 (20.00–97.9)	0.59	24.5 (20.00–25.89)	23.3 (20.00–23.40)	0.88
Testosterone, ng/dL	—	—	—	358.2 (187.2–486.8)	357.8 (186.3–560.2)	0.99
IGF-I, ng/mL	213.2 (149.9–270.2)	283.8 (204.2–349.7)	0.004	197.9 (122.0–237.0)	258.2 (152.8–308.2)	0.004
TV, h/d	2.2 (1.4–2.7)	2.1 (0.8–2.7)	0.63	2.3 (1.4–2.9)	1.8 (0.8–2.7)	0.04

NOTE: Mixed models (SAS Proc Mixed) were used to estimate means by sex while adjusting for age and sibling pairs. Abbreviations: TSH, thyroid-stimulating hormone; T4, free thyroxine; FSH, follicular-stimulating hormone; LH, luteinizing hormone; TV, television viewing.




Figure 1. Comparisons of lipid profiles between female cancer survivors and sibling controls (A) and male cancer survivors and sibling controls (B). No significant differences were found among females. Male cancer survivors had significantly elevated levels of total cholesterol, low-density lipoprotein cholesterol, and triglycerides. HDL, high-density lipoprotein; LDL, low-density lipoprotein.

survivors ranges between 21% and 54% (overweight) and 14% and 30% (obese) in some studies (8). Some investigators have found that pediatric cancer survivors do not have higher-than-normal BMIs (28, 30-32) and some survivors are at significant risk for being underweight (33). Variability in patient characteristics and study design, including length of follow-up, treatment, and appropriateness of controls, might explain these conflicting results.

Body composition is not routinely measured in childhood cancer survivor studies because these instruments are not easily accessed in the clinical setting. However, a European study (24), among others (6), confirmed that BMI was not as sensitive in detecting differences in body composition as fat estimates obtained by dual-energy X-ray absorptiometry (24). Male childhood acute lymphoblastic leukemia survivors who received cranial radiation had higher body fat, trunk fat, and serum lipids than did males who did not receive cranial radiation (24). The findings from our study are similar and show

that these results can be generalized to a population-based cohort of pediatric cancer survivors.

High body fat can be caused by endocrine dysfunction that can lead to growth hormone dysregulation. Abnormal endocrine function has been associated with cranial irradiation (8) in cancer survivors. We found IGF-I levels to be lower in survivors compared with sibling controls. Furthermore, cranial irradiation emerged as one of the strongest predictors of higher body fat (even after considering IGF-I levels), suggesting a more global influence of cranial irradiation on other factors that affect body fat, such as thyroid and sex hormones. This association was stronger for total body or trunk fat outcomes than BMI. Higher cranial irradiation doses were associated with greater body fat or BMI, although we could not statistically discriminate between 0 and 20 Gy and >20 Gy.

The findings of adverse lipid profiles, along with higher body fat in male cancer survivors suggest that they might be a high-risk group for adverse metabolic

Table 4. Determinants of measures of adiposity among 170 pediatric cancer survivors**A. Bivariate* and multivariate† determinants of BMI in 170 long-term pediatric cancer survivors, by sex**

Variable	Bivariate			Multivariate		
	Estimate	SEM	P	Estimate	SEM	P
Females						
Age, y	0.25	0.08	<0.003	0.20	0.08	0.02
Cyclophosphamide	-3.34	1.33	0.01	-3.00	1.34	0.03
Methotrexate	2.13	1.36	0.12	—	—	—
Cisplatin	-3.49	1.71	0.04	—	—	—
LH, μ U/mL	-0.09	0.05	0.09	—	—	—
Cranial irradiation	3.44	1.35	0.01	—	—	—
TV, h/d	1.17	0.54	0.03	1.02	0.52	0.06
Males						
Age, y	0.38	0.06	<0.001	0.43	0.06	<0.001
Cyclophosphamide	-2.77	1.02	0.008	-2.84	1.06	0.009
Cranial irradiation	1.95	1.02	0.06	—	—	—
IGF-I, ng/mL	0.01	0.005	0.04	0.012	0.005	0.01

B. Bivariate* and multivariate† determinants of percent body fat in 170 long-term pediatric cancer survivors, by sex

Variable	Bivariate			Multivariate		
	Estimate	SEM	P	Estimate	SEM	P
Females						
Age, y	0.37	0.13	0.005	0.31	0.13	0.02
Cyclophosphamide	-5.56	2.10	0.01	-4.66	2.09	0.03
Methotrexate	5.10	2.13	0.02	—	—	—
Cranial irradiation	7.10	2.02	<0.001	3.93	2.15	0.07
TV, h/d	2.92	0.81	<0.006	2.18	0.81	0.009
Males						
Age, y	0.27	0.13	0.04	0.34	0.11	0.003
Cyclophosphamide	-3.65	2.07	0.08	—	—	—
Cranial irradiation	5.92	2.02	0.004	5.82	1.91	0.003
TV, h/d	2.96	0.77	<0.003	2.6	0.74	<0.001

C. Bivariate* and multivariate† determinants of percent trunk fat in 170 long-term pediatric cancer survivors, by sex

Variable	Bivariate			Multivariate		
	Estimate	SEM	P	Estimate	SEM	P
Females						
Age, y	0.44	0.15	0.003	0.36	0.15	0.01
Cyclophosphamide	-6.03	2.41	0.01	-4.95	2.43	0.05
Methotrexate	5.84	2.42	0.02	—	—	—
Cranial irradiation	8.21	2.30	<0.006	4.85	2.50	0.05
TV, h/d	2.97	0.94	0.002	2.09	0.94	0.03
Males						
Age, y	0.55	0.13	<0.001	0.64	0.12	<0.0001
Cranial irradiation	6.73	2.15	0.002	6.44	2	0.002
TV, h/d	3.38	0.82	<0.001	2.98	0.78	<0.001

*Age-adjusted bivariate analyses.

†All variables listed in the bivariate analysis were considered for inclusion in the multivariate analysis.




Figure 2. Comparisons of adiposity measures (BMI, total body fat, and trunk fat) by increasing dosages of cranial irradiation in female (A) and male (B) cancer survivors. Increasing dosages of cranial irradiation did not significantly affect BMI, whereas there were increased levels of total body and trunk fat with cranial irradiation in both females and males.

cardiovascular outcomes. Fat, a metabolically active tissue, produces proinflammatory factors that contribute to vascular inflammation that can ultimately predispose the individual to atherosclerotic vascular lesions (34, 35). Total and low-density lipoprotein cholesterol are increased, whereas HDL cholesterol is decreased, in childhood cancer survivors (36-39). In our study, higher lipids and body fat, along with lower overall physical activity (as determined indirectly by the number of hours per day watching television), may contribute to these children being at potentially a greater risk for premature atherosclerotic cardiovascular disease.

Although our study did not evaluate the potential additive effects of video games and computer screen time, the possible effects of a sedentary lifestyle are

evident because television viewing hours was one of the strongest and most consistent predictors of body and trunk fat. Several studies (39-41), including a meta-analysis of physical activity interventions in cancer survivors by Schmitz (7), found overall physical deconditioning in survivors. Schmitz's meta-analysis of 32 studies (7) and others (42) show that exercise interventions in survivors had a moderate to large positive effect on cardiorespiratory outcomes (7). However, the child's risk from exercise must be carefully evaluated before recommending an exercise program because the cause of deconditioning can be multifactorial, including not only cardiac dysfunction but also pulmonary abnormalities, hormonal disturbances, obesity, and psychosocial issues (42).

Finally, therapy with the alkylating cytostatic agent, cyclophosphamide, is a significant independent predictor of lower BMI and body fat, an association that was found more often in females than males. This has not been well studied but is biologically plausible because of the other late effects of this drug in long-term survivors. Cyclophosphamide is associated with gonadal failure (43) and other late effects, including cardiac disease (44), decreased growth velocity (45, 46), and, in experimental animal models (47), apoptosis in bone (48, 49) and altered lipid metabolism (50, 51). Because our study design included a diverse study population, we cannot exclude the possibility that this finding may have been confounded by changes associated with other simultaneous treatments. However, extensive analyses that included propensity scores relating to cyclophosphamide therapy found no other associations (data not shown).

This study has some limitations. Non-Hispanic whites were our focus, and inferences to pediatric cancer survivors of other ethnicities must be cautiously considered. Our control group was smaller than our survivor group. We attempted to control for genetic and environmental influences by recruiting cancer survivors and their siblings and control for sibling pairs in the analyses.

In conclusion, body and trunk fat are greater in male pediatric cancer survivors than in their siblings, whereas

BMI is a less sensitive indicator of adiposity. Male cancer survivors have worse lipid profiles, watch a greater amount of television, and have other metabolic abnormalities associated with adiposity. For both female and male survivors, cranial irradiation and television viewing are associated with adiposity. Future studies should focus on early detection and promotion of safe lifestyle and physical activities in these patients at risk for both metabolic and drug- or radiation-related premature cardiovascular disease.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Grant Support

NIH (National Cancer Institute grants CA-79060 and CA-127642; National Institutes of Diabetes, Digestive and Kidney Diseases grant P01 DK-45734; and the General Clinical Research Center, which was funded by the Division of Research Resources of the NIH under grants M01-RR00054 and M01-RR00044).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 02/13/2010; revised 04/08/2010; accepted 05/19/2010; published OnlineFirst 07/20/2010.

References

- Mariotto AB, Rowland JH, Yabroff KR, et al. Long-term survivors of childhood cancers in the United States. *Cancer Epidemiol Biomarkers Prev* 2009;18:1033–40.
- National Cancer Policy Board (U.S.). In: Hewitt M, Weiner SL, Simone JV, editors. *Childhood cancer survivorship: improving care and quality of life*. Washington (DC): National Academies Press; 2003.
- Alvarez JA, Scully RE, Miller TL, et al. Long-term effects of treatments for childhood cancers. *Curr Opin Pediatr* 2007;19:23–31.
- Larsson SC, Wolk A. Overweight and obesity and incidence of leukemia: a meta-analysis of cohort studies. *Int J Cancer* 2008;122:1418–21.
- Reilly JJ, Venthani JC, Newell J, et al. Risk factors for excess weight gain in children treated for acute lymphoblastic leukaemia. *Int J Obes Relat Metab Disord* 2000;24:1537–41.
- Nysom K, Holm K, Michaelsen KF, et al. Degree of fatness after treatment for acute lymphoblastic leukemia in childhood. *J Clin Endocrinol Metab* 1999;84:4591–6.
- Schmitz KH, Holtzman J, Courneya KS, et al. Controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. *Cancer Epidemiol Biomarkers Prev* 2005;14:1588–95.
- Oeffinger KC, Mertens AC, Sklar CA, et al. Obesity in adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. *J Clin Oncol* 2003;21:1359–65.
- Garmey EG, Liu Q, Sklar CA, et al. Longitudinal changes in obesity and body mass index among adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. *J Clin Oncol* 2008;26:4639–45.
- Ross JA, Oeffinger KC, Davies SM, et al. Genetic variation in the leptin receptor gene and obesity in survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. *J Clin Oncol* 2004;22:3558–62.
- Reilly JJ, Kelly A, Ness P, et al. Premature adiposity rebound in children treated for acute lymphoblastic leukemia. *J Clin Endocrinol Metab* 2001;86:2775–8.
- Messiah SE, Arheart KL, Luke B, et al. Relationship between body mass index and metabolic syndrome risk factors among US 8- to 14-year-olds, 1999 to 2002. *J Pediatr* 2008;153:215–21.
- Messiah SE, Arheart KL, Lipshultz SE, et al. Body mass index, waist circumference, and cardiovascular risk factors in adolescents. *J Pediatr* 2008;153:845–50.
- Alvarez JA, Miller TL, Starc TJ, McGrath K, Lipshultz SE. Preventive cardiology. In: McInarney T, Hoekelman RA, Adams HM, Nelson NM, Weitzman ML, Wilson MH, editors. *American Academy of Pediatrics: Pediatric Primary Care, 5/e*. St Louis: Elsevier Mosby; 2008.
- Hinkle AS, Proukou C, French CA, et al. A clinic-based, comprehensive care model for studying late effects in long-term survivors of pediatric illnesses. *Pediatrics* 2004;113:1141–5.
- Freedman DS, Ogden CL, Berenson GS, et al. Body mass index and body fatness in childhood. *Curr Opin Clin Nutr Metab Care* 2005;8:618–23.
- Lohman TG, Roche AF, Martorell R. *Anthropometric standardization manual*. Champaign (IL): Human Kinetics Publishers; 1988.
- Centers for Disease Control and Prevention. Defining overweight and obesity. Available from: <http://www.cdc.gov/nccdphp/dnpa/obesity/defining.htm> (accessed February 7, 2010).
- Margulies L, Horlick M, Thornton JC, et al. Reproducibility of pediatric whole body bone and body composition measures by dual-energy X-ray absorptiometry using the GE Lunar Prodigy. *J Clin Densitom* 2005;8:298–304.
- Dietz WH, Jr., Gortmaker SL. Do we fatten our children at the television set? Obesity and television viewing in children and adolescents. *Pediatrics* 1985;75:807–12.
- Littell RC, Milliken GA, Stroup WW, et al. *SAS system for mixed models*. Cary (NC): SAS Institute; 1996.
- Constine LS, Woolf PD, Cann D, et al. Hypothalamic-pituitary dysfunction after radiation for brain tumors. *N Engl J Med* 1993;328:87–94.
- Baillargeon J, Langevin AM, Lewis M, et al. Therapy-related changes in body size in Hispanic children with acute lymphoblastic leukemia. *Cancer* 2005;103:1725–9.

24. Jarfelt M, Lannering B, Bosaeus I, et al. Body composition in young adult survivors of childhood acute lymphoblastic leukaemia. *Eur J Endocrinol* 2005;153:81–9.
25. Murphy AJ, Wells JC, Williams JE, et al. Body composition in children in remission from acute lymphoblastic leukemia. *Am J Clin Nutr* 2006;83:70–4.
26. Warner JT, Evans WD, Webb DK, et al. Body composition of long-term survivors of acute lymphoblastic leukaemia. *Med Pediatr Oncol* 2002;38:165–72.
27. Janiszewski PM, Oeffinger KC, Church TS, et al. Abdominal obesity, liver fat, and muscle composition in survivors of childhood acute lymphoblastic leukemia. *J Clin Endocrinol Metab* 2007;92:3816–21.
28. Gurney JG, Ness KK, Stovall M, et al. Final height and body mass index among adult survivors of childhood brain cancer: Childhood Cancer Survivor Study. *J Clin Endocrinol Metab* 2003;88:4731–9.
29. Lustig RH, Post SR, Srivannaboorn K, et al. Risk factors for the development of obesity in children surviving brain tumors. *J Clin Endocrinol Metab* 2003;88:611–6.
30. Meacham LR, Gurney JG, Mertens AC, et al. Body mass index in long-term adult survivors of childhood cancer: a report of the Childhood Cancer Survivor Study. *Cancer* 2003;103:1730–9.
31. Van Dongen-Melman JE, Hokken-Koelega AC, Hahlen K, et al. Obesity after successful treatment of acute lymphoblastic leukemia in childhood. *Pediatr Res* 1995;38:86–90.
32. Davies HA, Didcock E, Didi M, et al. Growth, puberty and obesity after treatment for leukaemia. *Acta Paediatr* 1995;Suppl 411:45–50.
33. Meacham LR, Gurney JG, Mertens AC, et al. Body mass index in long-term adult survivors of childhood cancer: a report of the Childhood Cancer Survivor Study. *Cancer* 2005;103:1730–9.
34. Murdolo G, Smith U. The dysregulated adipose tissue: a connecting link between insulin resistance, type 2 diabetes mellitus and atherosclerosis. *Nutr Metab Cardiovasc Dis* 2006;16 Suppl 1:S35–8.
35. Fisher SD, Miller TL, Lipshultz SE. Impact of HIV and highly active antiretroviral therapy on leukocyte adhesion molecules, arterial inflammation, dyslipidemia, and atherosclerosis. *Atherosclerosis* 2006;185:1–11.
36. Lipshultz SE, Lipsitz SR, Hinkle AS, et al. Cardiovascular status, subsequent risk, and associated factors in long-term survivors of childhood cancer in a population-based NCI study. *Circulation* 2005;112:II–476.
37. Oeffinger KC, Buchanan GR, Eshelman DA, et al. Cardiovascular risk factors in young adult survivors of acute lymphoblastic leukemia. *J Pediatr Hematol Oncol* 2001;23:424–30.
38. Link K, Moell C, Garwicz S, et al. Growth hormone deficiency predicts cardiovascular risk in young adults treated for acute lymphoblastic leukemia in childhood. *J Clin Endocrinol Metab* 2004;89:5003–12.
39. Meacham LR, Chow EJ, Ness KK, et al. Cardiovascular risk factors in adult survivors of pediatric cancer—a report from the childhood cancer survivor study. *Cancer Epidemiol Biomarkers Prev* 2010;19:170–81.
40. De Caro E, Fioredda F, Calevo MG, et al. Exercise capacity in apparently healthy survivors of cancer. *Arch Dis Child* 2006;91:47–51.
41. Adams MJ, Lipsitz SR, Colan SD, et al. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. *J Clin Oncol* 2004;22:3139–48.
42. Miller TL, Horgan S, Lipshultz SE. Exercise rehabilitation of pediatric patients with cardiovascular disease. *Prog Pediatr Cardiol* 2005;20:27–37.
43. Grigg AP, McLachlan R, Zaja J, et al. Reproductive status in long-term bone marrow transplant survivors receiving busulfan-cyclophosphamide (120 mg/kg). *Bone Marrow Transplant* 2000;26:1089–95.
44. Simbre VC, Duffy SA, Dadlani GH, et al. Cardiotoxicity of cancer chemotherapy: implications for children. *Paediatr Drugs* 2005;7:187–202.
45. Wojcik D, Barq E, Niedzielska E, et al. Analysis of some risk factors for abnormal growth velocity in children treated with haematopoietic stem cell transplantation. *Med Wieku Rozwoi* 2006;10:841–8.
46. Okunieff P, Barrett AJ, Phang SE, et al. Circulating basic fibroblast growth factor declines during CyTBI bone marrow transplantation. *Bone Marrow Transplant* 1999;23:1117–21.
47. Kim Y, Brown TP, Pantin-Jackwood MJ. Lesions induced in broiler chickens by cyclophosphamide treatment. *Vet Hum Toxicol* 2003;45:121–3.
48. Xian CJ, Cool JC, van Gangelen J, et al. Effects of etoposide and cyclophosphamide acute chemotherapy on growth plate and metaphyseal bone in rats. *Cancer Bill Ther* 2006;6:e1–8.
49. Zilberman O, Nasman M, Forsberg C-M, et al. Effects of cyclophosphamide on the femoral epiphyseal growth plate in young Sprague-Dawley rats. *Acta Odontologica Scandinavica* 2002;60:208–12.
50. Lespine A, Azema C, Gafvels M, et al. Lipoprotein lipase regulation in the cyclophosphamide-treated rabbit: dependence on nutritional status. *J Lipid Res* 1993;34:23–36.
51. Lespine A, Chap H, Perret B. Impaired secretion of heart lipoprotein lipase in cyclophosphamide-treated rabbit. *Biochim Biophys Acta* 1997;1345:77–85.